Drug Price Transparency Act
Latest action · Oct 10, 2018 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedSep 27, 2018
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Drug Price Transparency Act
This bill requires the Centers for Medicare & Medicaid Services to report on the feasibility of basing payment rates for prescription drugs under Medicare and Medicare Advantage on the average price of such drugs in countries that are members of the Organization for Economic Cooperation and Development (an intergovernmental organization focused on global economic development).
Cosponsors 1
Members who signed on, in the order they did. All signed on Sep 27, 2018.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-VT | Peter Welch | Original | Sep 27, 2018 |
Committees 2
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Sep 27, 2018 |
| House | Ways and Means Committee | Referred Sep 27, 2018 |
| Health Subcommittee | Referred Oct 10, 2018 |
Actions 3
Everything that happened, newest first.
- Oct 10, 2018Referred to the Subcommittee on Health.
- Sep 27, 2018Introduced in House
- Sep 27, 2018Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 164, no. 160, September 27, 2018, page H9152.
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To provide for a study and report on the feasibility of basing reimbursement rates for Medicare part B drugs and covered part D drugs on the average prices for such drugs in the member-states of the Organization for Economic Cooperation and Development.
- Short Titles as Introduced
- Drug Price Transparency Act
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- Sep 27, 2018Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.
